IN8bio, Inc
IN8bio, Inc. is a clinical-stage biotechnology company developing genetically modified gamma-delta T cell therapies for cancer. The company is focused on advancing its lead program INB-100 and earlier-stage pipeline assets, while relying on external financing and collaborations to fund development.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLead therapeutic candidates in human development, centered on INB-100 for cancer.
Earlier-stage programs being advanced through discovery and preclinical work, including INB-400.
Genetically modified gamma-delta T cell technology, manufacturing processes, and supporting know-how.
Potential partnering, licensing, and other third-party arrangements around pipeline assets.
Customers
IN8bio does not yet sell commercial products, so its near-term counterparties are clinical investigators, hospitals, contract research organizations, and contract manufacturing organizations that support development. If approved, its therapies would be sold to oncology treatment centers and administered by specialized healthcare professionals for cancer patients. The company also seeks strategic partners for selected programs to help fund development and broaden commercialization options.
They run studies for INB-100 and other candidates, enabling patient enrollment, data generation, and regulatory progress.
They provide preclinical, clinical, and manufacturing services needed to advance the pipeline without in-house scale.
These would be the commercial delivery points for approved cell therapies, where specialist physicians administer treatment.
Biopharma partners may license or co-develop assets such as INB-400 and earlier-stage programs to share cost and risk.
Strategy
The company’s near-term strategy is to advance INB-100, progress preclinical assets, and strengthen internal R&D capabilities while preserving cash. It is also actively seeking funding and partnerships for INB-400 and earlier-stage programs, using collaborations and licensing to extend runway and reduce capital intensity.
The lead program is the main value driver and the most advanced asset in the pipeline.
Collaborations can fund development and reduce the company’s capital burden.
The company has disclosed substantial doubt about going concern without additional financing.
A stronger internal platform improves execution if programs reach later-stage development or approval.
Geography
IN8bio is headquartered in New York and currently concentrates its development and planned commercialization efforts in the United States. The company has not disclosed meaningful country revenue because it has not generated product revenue, and its business remains pre-commercial. Its operating model depends on U.S.-based research, clinical development, and regulatory execution, with potential selective partnerships in other markets later.
Risks
IN8bio is a pre-revenue biotech with substantial going-concern risk, so its ability to continue operations depends on raising capital and/or securing partnerships. Its pipeline also depends on clinical success, regulatory approval, and reliable third-party manufacturing and IP access, all of which are common failure points in cell therapy development.
- Insufficient liquidity and going-concern uncertaintyImpact: CriticalLikelihood: High
Cash is not expected to fund operations beyond the disclosed runway without new capital.
Exposure - Clinical trial and regulatory failureImpact: HighLikelihood: High
Pipeline value depends on successful human data and regulatory clearance for cell therapies.
Exposure: INB-100 and future product candidates
- Single-source supplier dependenceImpact: HighLikelihood: Medium
Critical manufacturing inputs such as automated manufacturing devices and lentiviral vectors come from a single third-party supplier.
Exposure: Manufacturing continuity and trial supply
- Intellectual property and license complianceImpact: HighLikelihood: Medium
The company depends on third-party licenses; breach or loss of rights could block development and commercialization.
Exposure: Licensed product candidates and platform rights
- Cybersecurity and data privacy incidentsImpact: MediumLikelihood: Medium
R&D, clinical, and vendor data are sensitive and exposed to ransomware, supply-chain, and remote-work threats.
Exposure - Key-person dependenceImpact: MediumLikelihood: Medium
The company is highly dependent on its co-founders and scientific leadership for execution.
Exposure: Pipeline development and financing credibility
Accounting
Judgemental itemsManagement has disclosed substantial doubt about the ability to continue without additional financing.
Impact: Affects financial statement presentation and investor assessment of survival risk
ATM programs, private placements, and warrant exercises drive cash inflows and may create complex equity classification issues.
Impact: Affects cash, shareholders' equity, and dilution analysis
Clinical, preclinical, CRO, and CMO costs are expensed as incurred and dominate the income statement.
Impact: Drives operating loss and quarterly volatility
Employee and consultant awards are a meaningful non-cash cost for a development-stage biotech.
Impact: Inflates operating expenses and affects comparability
Principal payments on leases were disclosed as a financing cash outflow and lease liabilities affect balance sheet leverage.
Impact: Affects cash flow classification and liabilities
Similar listed companies
Publicly listed companies with a comparable business focus.
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
iBio, Inc.
IBIO · Pharmaceutical Preparations
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026